Sector News

ConvaTec strengthens its board

August 15, 2017
Life sciences

ConvaTec Group has appointed Dr Regina Benjamin and Margaret Ewing as non-executive directors with immediate effect.

Benjamin was United States surgeon general from 2009 – 2013 and is currently a non-executive director of Diplomat Pharmacy, Kaiser Foundation Hospitals and Health Plan, and Ascension Hospital System. She is a former non-executive director of Alere.

From 1992-2004 she served on the board of the Medical Association of Alabama, and in 1995, became the first young physician to be elected to the American Medical Association Board of Trustees. In 2008, she chaired the Federation of State Medical Licensing Boards.

Benjamin is CEO and practising physician at the Bayou La Batre Rural Health Clinic in Alabama, which she founded in 1990 and holds an endowed chair in Public Health Sciences at Xavier University of Louisiana. She will immediately join the corporate responsibility committee.

Ewing is currently a trustee of the board and chairman of the finance and audit committee of Great Ormond Street Hospital Children’s Charity. She is also the independent external member of the audit committee of the Lawn Tennis Association.

Ewing was previously a non-executive director of Standard Chartered, Whitbread and the Confederation of British Industry and the independent external member of the audit committee of John Lewis Partnership.

She was a corporate finance partner of Deloitte LLP between 1987-1999, returning to Deloitte in 2007 as a senior partner and retiring from the firm in 2012.

During the period 2007-2012 Mrs Ewing was vice-chairman and a member of the firm’s executive committee and the board, senior partner of the London practice and latterly managing partner for public policy, quality and risk.

Ewing was group chief financial officer of Trinity Mirror from 2000-2002 and of BAA plc from 2002-2006. She was also a member of the financial reporting review panel between 2011-2014. She will immediately join the audit and risk committee and corporate responsibility committee.

It was previously announced that Dr Raj Shah would be leaving the board of ConvaTec on 8 September 2017 following the reduction by Nordic Capital of its shareholding in the company.

Dr Ros Rivaz, who was appointed a non-executive director of the company on 21 June , will immediately join the nominations and remuneration committees in place of Shah.

Chairman Sir Christopher Gent said: “I am delighted to announce two appointments of individuals who bring a wealth of experience and knowledge to the Board.

“Also with the appointments of Regina and Margaret, we have fulfilled our promise to shareholders that we would appoint a Board which would comprise a majority of independent Directors and which would reflect the requirements and advantages of gender diversity.

“We look forward to benefiting from their contribution to the future success of the Company.”

Source: StockMarketWire

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach